Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Ohio: - Aultman Alliance Community Hospital — Alliance, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- MetroHealth Medical Center — Cleveland, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Sites in Ohio: - Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Oncology Hematology Care Inc-Kenwood — Cincinnati, Ohio
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Ohio: - Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Miami Valley Hospital — Dayton, Ohio
- Miami Valley Hospital North — Dayton, Ohio
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Ohio: - Oncology Hematology Care Inc — Cincinnati, Ohio
- Oncology Hematology Care — Cincinnati, Ohio
- Oncology Hematology Care Inc — Cincinnati, Ohio
- Oncology Hematology Care Inc — Fairfield, Ohio
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Ohio: - Clinical Study Site — Columbus, Ohio
- Clinical Study Sites — Lebanon, Ohio
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Ohio: - Aultman Hospital — Canton, Ohio
- Cleveland Clinic — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T — Columbus, Ohio
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Ohio: - Oncology Hematology Care (OHC), Inc — Cincinnati, Ohio
- University Hospitals Case Medical Center — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Ohio: - Genesis Cancer Care Center /ID# 239190 — Zanesville, Ohio
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Ohio: - University of Cincinnati Medical Center ( Site 0119) — Cincinnati, Ohio
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
- Case Western (University Hospitals Case Medical Center) — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Ohio State University Wexner Medical Center — Columbus, Ohio
Phase 3 Recruiting Industry
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Sponsor: Amgen
NCT ID: NCT07005128
Sites in Ohio: - Oncology Hematology Care, Inc — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Ohio: - Local Institution - 0163 — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Ohio: - The Ohio State University- James Cancer Hospital — Columbus, Ohio
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Ohio: - Gabrail Cancer Center Research — Canton, Ohio
- The Christ Hospital Cancer Center — Cincinnati, Ohio
- University of Cincinnati Medical Center — Cincinnati, Ohio
- The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Academic/Other
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Ohio: - Toledo Clinic Cancer Center - Toledo — Toledo, Ohio
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in Ohio: - University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Local Institution - 0284 — Columbus, Ohio
Phase 3 Recruiting Industry
This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enrolled participants will be randomized 2:…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Ohio: - University Hospitals Seidman Cancer Center — Sandusky, Ohio
- Taylor Cancer Research Foundation — Toledo, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (here…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06074588
Sites in Ohio: - University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0015) — Cincinnati, Ohio
Phase 3 Recruiting Industry
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan an…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06170788
Sites in Ohio: - University Hospitals Cleveland Medical Center ( Site 0119) — Cleveland, Ohio
Phase 3 Recruiting Industry
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Ohio: - Strecker Cancer Center-Belpre — Belpre, Ohio
- Cleveland Clinic Mercy Hospital — Canton, Ohio
- Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- Adena Regional Medical Center — Chillicothe, Ohio